Addressing the gaps in global policy and research for non-communicable diseases
Related news and resources
Value of investment on NCDs: Impact on health outcomes in low- and middle-income countries
In new research commissioned by IFPMA, Airfinity has determined that an additional investment of 1% of GDP toward domestic general government health expenditure in low- and middle-income countries (LMICs) would amount to a US$ 310 billion additional investment, representing a 33% increase in current spending. This research is a response to the UHC 2030 action agenda...
Read more
From innovation to access: Pharmaceutical industry priorities ahead of the 4th UN High-Level Meeting on NCDs and Mental Health
Non-communicable diseases (NCDs), such as diabetes, cardiovascular, renal and metabolic diseases, cancer, chronic respiratory diseases, mental health and neurological diseases, are one of the greatest global health and economic threats we face in our lifetime. Since 2000, global deaths due to NCDs have increased rapidly, even as deaths due to communicable diseases have declined. The...
Read more
156th WHO Executive Board (EB156): Individual statement on non-communicable diseases
On 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).
Read more